NCT03720366View on ClinicalTrials.gov

A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

September 22, 2023

Study Completion Date

December 22, 2023

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

enasidenib

enasidenib

DRUG

Arm 1 probes

caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole

DRUG

Arm 2 Probes

digoxin and rosuvastatin

DRUG

Arm 3 probes

pioglitazone

Trial Locations (10)

2139

Local Institution - 103, Concord

3084

Local Institution - 102, Heidelberg

3141

Local Institution - 101, Melbourne

3168

Local Institution - 106, Clayton

5000

Local Institution - 107, Adelaide

5505

Local Institution - 201, Seoul

6009

Local Institution - 105, Nedlands

NSW

Local Institution - 104, Waratah

06351

Local Institution - 203, Seoul

110-744

Local Institution - 202, Seoul

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT03720366 - A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients | Biotech Hunter | Biotech Hunter